ArticleArchives of gynecology and obstetrics2025
Diagnostic yield of chromosomal microarray to examine the genetic factors associated with fetal aberrant right subclavian artery.
Article in Archives of gynecology and obstetrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A simple nomogram tool for predicting fetal chromosomal abnormalities based on ultrasound soft markers: a research note.BMC research notes · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeThe primary objective was to find the risk factors that increase the probability of chromosomal abnormalities in fetal aberrant right subclavian artery (ARSA). Secondary objectives were to assess the factors which impact the adverse pregnancy outcomes in ARSA fetuses.
methodsThis retrospective study included a total of 104 pregnant women whose fetuses were diagnosed with ARSA from January 2020 to July 2024, with subsequent chromosomal microarray analysis (CMA) performed.
resultsAmong the 104 cases of ARSA in this study, 46 (44.2%) were classified as isolated ARSA and 58 (55.8%) as non-isolated ARSA. Classification of non-isolated ARSA based on ultrasound soft marker abnormalities and structural abnormalities showed that an increase in the number of combined ultrasound soft marker abnormalities was associated with increased fetal chromosomal abnormalities and pathogenicity. In fetuses with structural abnormalities and ultrasonographic soft markers, they have more microarray abnormalities and higher pathogenicity compared to ARSA with only a single soft marker. The chromosomal abnormalities in ARSA fetuses predominantly manifest as trisomy 21, partial segmental microduplications, and microdeletions. Logistic regression analysis indicated that the presence of ultrasonographic soft marker abnormalities alongside ARSA serves as a risk factor for adverse pregnancy outcomes in ARSA fetuses.
conclusionIn contrast to isolated ARSA, chromosomal disorders indicate a significant risk in ARSA accompanied by ultrasound abnormalities, and the risk is closely related to the number of ultrasonographic soft marker abnormalities. In addition, the combination of ultrasonographic soft marker abnormalities was a risk factor for adverse pregnancy outcomes in ARSA, while maternal age, structural abnormalities, polyhydramnios, and intrauterine growth restriction were not associated with it.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.